Thiogenesis Therapeutics, Corp.
TTI.V
TSX
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -259.41% | -188.42% | -86.53% | 47.12% | 38.74% |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 697.42% | 222.11% | 50.17% | 70.07% | -59.91% |
| Change in Net Operating Assets | 82.61% | 1,391.53% | 131.13% | -67.89% | -661.35% |
| Cash from Operations | -151.94% | -110.30% | 60.95% | 24.86% | 17.21% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 54,351.43% | -- | -- | -93.84% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 54,162.75% | -- | -- | -94.01% | -- |
| Foreign Exchange rate Adjustments | -717.65% | 144.44% | 82.98% | -169.59% | 123.61% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 299.52% | -109.19% | 49.57% | -108.44% | 19.92% |